Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents |
| |
| Authors: | Fahad S. Aldawsari Rodrigo Aguayo-Ortiz Kanishk Kapilashrami Jakyung Yoo Minkui Luo José L. Medina-Franco |
| |
| Affiliation: | 1. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada,;2. Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, México City, Mexico,;3. Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, and;4. Life Science Research Institute, Daewoong Pharmaceutical Co., Ltd., Pogok-Eup, Republic of Korea |
| |
| Abstract: | Resveratrol is a natural polyphenol with plethora of biological activities. Resveratrol has previously shown to decrease DNA-methyltransferase (DNMT) enzymes expression and to reactivate silenced tumor suppressor genes. Currently, it seems that no resveratrol analogs have been developed as DNMT inhibitors. Recently, we reported the synthesis of resveratrol-salicylate derivatives and by examining the chemical structure of these analogs, we proposed that these compounds could exhibit DNMT inhibition especially that they resembled NSC 14778, a compound we previously identified as a DNMT inhibitor by virtual screening. Indeed, using in vitro DNMT inhibition assay, some of the resveratrol-salicylate analogs we screened in this work that showed selective inhibition against DNMT3 enzymes which were greater than resveratrol. A molecular docking study revealed key binding interactions with DNMT3A and DNMT3B enzymes. In addition, the most active analog, 10 showed considerable cytotoxicity against three human cancer cells; HT-29, HepG2 and SK-BR-3, which was greater than resveratrol. Further studies are needed to understand the anticancer mechanisms of these derivatives. |
| |
| Keywords: | Aspirin chemoprevention DNMT docking resveratrol |
|
|
